Form 4: Director Erin Lavelle Receives Jade Biosciences Stock Options

Director Erin Lavelle was granted 34,843 stock options in Jade Biosciences, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Erin Lavelle acquired 34,843 stock options in Jade Biosciences, Inc. (JBIO).
• The options have an exercise price of $15.22 per share.
• The grant date for these options is June 9, 2026.
• The options are set to expire on June 8, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant signal regarding company performance.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the reporting person's continued service to the issuer.

Future Outlook

The options vest in full on the earlier of June 9, 2027, or the date of the next annual meeting of stockholders, subject to continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized toward long-term clinical and commercial milestones.

Comparison to Industry Standards

• The grant of stock options to non-executive directors is consistent with standard compensation packages for small-cap biotechnology firms.
• The ten-year expiration term is standard practice for equity incentive plans in the U.S. public markets.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on June 9, 2027, or the next annual meeting date.

Key Dates

Keywords

Jade Biosciences, JBIO, Form 4, Insider Trading, Stock Options, Director Compensation